Literature DB >> 24378917

Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.

Virginia A Moyer.   

Abstract

DESCRIPTION: Update of the 2004 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for lung cancer.
METHODS: The USPSTF reviewed the evidence on the efficacy of low-dose computed tomography, chest radiography, and sputum cytologic evaluation for lung cancer screening in asymptomatic persons who are at average or high risk for lung cancer (current or former smokers) and the benefits and harms of these screening tests and of surgical resection of early-stage non-small cell lung cancer. The USPSTF also commissioned modeling studies to provide information about the optimum age at which to begin and end screening, the optimum screening interval, and the relative benefits and harms of different screening strategies. POPULATION: This recommendation applies to asymptomatic adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. RECOMMENDATION: The USPSTF recommends annual screening for lung cancer with low-dose computed tomography in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. (B recommendation).

Entities:  

Mesh:

Year:  2014        PMID: 24378917     DOI: 10.7326/M13-2771

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  671 in total

1.  Using Implementation Science to Disseminate a Lung Cancer Screening Education Intervention Through Community Health Workers.

Authors:  Lovoria B Williams; Brent J Shelton; Maria L Gomez; Yazan D Al-Mrayat; Jamie L Studts
Journal:  J Community Health       Date:  2021-02

2.  Management of subsolid pulmonary nodules in CT lung cancer screening.

Authors:  Marjolein A Heuvelmans; Matthijs Oudkerk
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

Review 3.  Health screening for older people-what are the current recommendations?

Authors:  S G Sazlina
Journal:  Malays Fam Physician       Date:  2015-04-30

Review 4.  Implementing lung cancer screening in the real world: opportunity, challenges and solutions.

Authors:  Robert J Optican; Caroline Chiles
Journal:  Transl Lung Cancer Res       Date:  2015-08

Review 5.  Global trends of lung cancer mortality and smoking prevalence.

Authors:  Farhad Islami; Lindsey A Torre; Ahmedin Jemal
Journal:  Transl Lung Cancer Res       Date:  2015-08

6.  Complication Rates and Downstream Medical Costs Associated With Invasive Diagnostic Procedures for Lung Abnormalities in the Community Setting.

Authors:  Jinhai Huo; Ying Xu; Tommy Sheu; Robert J Volk; Ya-Chen Tina Shih
Journal:  JAMA Intern Med       Date:  2019-03-01       Impact factor: 21.873

7.  Evaluation of models for predicting the probability of malignancy in patients with pulmonary nodules.

Authors:  You Li; Hui Hu; Ziwei Wu; Ge Yan; Tangwei Wu; Shuiyi Liu; Weiqun Chen; Zhongxin Lu
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

8.  Assessment of Lung Cancer Screening Program Websites.

Authors:  Stephen D Clark; Daniel S Reuland; Chineme Enyioha; Daniel E Jonas
Journal:  JAMA Intern Med       Date:  2020-06-01       Impact factor: 21.873

9.  Potential Racial Disparities Using Current Lung Cancer Screening Guidelines.

Authors:  Srinadh Annangi; Snigdha Nutalapati; Marilyn G Foreman; Rathi Pillai; Eric L Flenaugh
Journal:  J Racial Ethn Health Disparities       Date:  2018-05-04

10.  Multilevel Small-Area Estimation of Multiple Cigarette Smoking Status Categories Using the 2012 Behavioral Risk Factor Surveillance System.

Authors:  Zahava Berkowitz; Xingyou Zhang; Thomas B Richards; Lucy Peipins; S Jane Henley; James Holt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-10       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.